The MerLion pipeline is focused toward the discovery and development of novel antibiotics for conditions where there is clear unmet clinical need. Clinical development projects are supported by innovative anti-infectives research and partnered discovery programmes which continue to deliver novel candidates
| Research | Development | ||||
| Optimization | Preclinical | Phase I | Phase II | Phase III | |
| Antibacterial | |||||
| Finafloxacin (oral) |
 |
||||
| Finafloxacin (iv) |
|
||||
| Friulimicin (iv) |
|
||||
| Friulimicin (topical) |
|
||||
| Lipopeptide Programme (MRSA/VRE/SSTI) |
|
||||
| Hybrid Programme (Gram + and -) |
|
||||
| Anti-Virulence Programme | |
||||
| Oncology | |||||
| Macrolide Programme | |
||||